Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS 28  OCT 22  Current-awareness alert (SDI) setup and editing
                  enhanced
 NEWS 29  OCT 22  WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                  Applications

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:08:36 ON 22 OCT 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.89       1.89

FILE 'REGISTRY' ENTERED AT 11:13:42 ON 22 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 OCT 2008  HIGHEST RN 1064205-90-8
DICTIONARY FILE UPDATES:  21 OCT 2008  HIGHEST RN 1064205-90-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10551414.str
```





```
chain nodes :
7  8  9  10  11  12
ring nodes :
1  2  3  4  5  6
chain bonds :
4-7  7-8  8-9  9-10  10-11
ring bonds :
1-6  1-2  2-3  3-4  4-5  5-6
exact/norm bonds :
4-7  7-8  8-9  9-10  10-11
normalized bonds :
1-6  1-2  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:CLASS  11:CLASS  12:CLASS  14:CLASS
Generic attributes :
11:
Saturation               : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System    : Monocyclic
12:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System    : Monocyclic

Element Count :
Node 11: Limited
    C,C5
    N,N1

Node 12: Limited
    C,C3
    O,O1
    N,N1
    S,S0




L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:15:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    29906 TO ITERATE

  6.7% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       587775 TO   608465
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:15:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   602538 TO ITERATE

100.0% PROCESSED   602538 ITERATIONS                              33 ANSWERS
SEARCH TIME: 00.00.07

L3           33 SEA SSS FUL L1

=> s l3 and caplus/lc
      59456180 CAPLUS/LC
L4          32 L3 AND CAPLUS/LC

=> s l3 not l4
L5           1 L3 NOT L4

=> d
```

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 794492-66-3 REGISTRY
ED Entered STN: 08 Dec 2004
CN 4-Pyridineacetic acid, α-[2-[4-[5-oxazolyl]phenyl]hydrazinylidene]-,
    (αZ)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4-Pyridineacetic acid, α-[[4-[5-oxazolyl]phenyl]hydrazono]-,
    (αZ)- (9CI)
FS STEREOSEARCH
MF C16 H12 N4 O3
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   186.43     188.32

FILE 'CAPLUS' ENTERED AT 11:15:31 ON 22 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Oct 2008  VOL 149 ISS 17
FILE LAST UPDATED: 21 Oct 2008  (20081021/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 11:08:36 ON 22 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 11:13:42 ON 22 OCT 2008
L1             STRUCTURE UPLOADED
L2               0 S L1
L3              33 S L1 FULL
L4              32 S L3 AND CAPLUS/LC
L5               1 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 11:15:31 ON 22 OCT 2008

=> s l4
L6              2 L4

=> d ibib abs hitstr 1-2
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1390731 CAPLUS
DOCUMENT NUMBER: 148:158934
TITLE: Orally administered amyloidophilic compounds are effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner
AUTHOR(S): Kawasaki, Yuri; Kasegawa, Keiichi; Chen, Chun-jen; Tenya, Kenta; Sakasegawa, Yuji; Doh-ura, Katsumi
CORPORATE SOURCE: Department of Prion Research, Tohoku University Graduate School of Medicine, Sendai, Japan
SOURCE: Journal of Virology (2007), 81(23), 12889-12898
CODEN: JOVIAM; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The establishment of effective therapeutic interventions for prion diseases is necessary. We report on a newly developed amyloidophilic compound that displays therapeutic efficacy when administered orally. This compound inhibited abnormal prion protein formation in prion-infected neuroblastoma cells in a prion strain-dependent manner effectively for RML prion and marginally for 22L prion and Fukuoka-1 prion. When the high-est dose (2.4% [wt/wt] in feed) was given orally to cerebrally RML prion-inoculated mice from inoculation until the terminal stage of disease, it extended the incubation periods by 2.3 times compared to the control. The compound exerted therapeutic efficacy in a prion strain-dependent manner such as that observed in the cell culture study: most effective for RML prion, less effective for 22L prion or Fukuoka-1 prion, and marginally effective for 263K prion. Its effectiveness depended on an earlier start of administration. The glycoform pattern of the abnormal prion protein in the treated mice was modified and showed predominance of the diglycosylated form, which resembled that of 263K prion, suggesting that diglycosylated forms of abnormal prion protein might be least sensitive or resistant to the compound. The mechanism of the prion strain-dependent effectiveness needs to be elucidated and managed. Nevertheless, the identification of an orally available amyloidophilic chemical encourages the pursuit of chemotherapy for prion diseases.
IT 774236-55-4
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally administered amyloidophilic compds. are effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner)
RN 774236-55-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857947 CAPLUS
DOCUMENT NUMBER: 141:350274
TITLE: Preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone derivatives as inhibitors of agglutination and/or deposition of an amyloid protein or amyloid-like protein
INVENTOR(S): Kawagoe, Keiichi; Motoki, Kayoko; Odagiri, Takashi; Suzuki, Naoyoshi; Chen, Chun-Jen; Mimura, Tetsuya
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087641	A1	20041014	WO 2004-JP4607	20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521056	A1	20041014	CA 2004-2521056	20040331
EP 1612204	A1	20060104	EP 2004-724752	20040331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 20060276637	A1	20061207	US 2005-551414	20050930
PRIORITY APPLN. INFO.:			JP 2003-94257	A 20030331
			WO 2004-JP4607	W 20040331
OTHER SOURCE(S):	MARPAT 141:350274			
GI				

AB Compds. represented by the general formula (I), salts thereof, or solvates of either [R1, R2 = H, alkyl, alkenyl, alkynyl, aralkyl, NH2, alkylamino, cyano, halo, haloalkyl, haloalkenyl, haloalkynyl, COOR, alkoxycarbonyl, CONR2, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-hydroxyalkylcarbamoyl, each (un)substituted aryl, (un)saturated 5- to 7-membered heterocyclyl, (un)saturated bi- or tricyclo condensed heterocyclyl, arylalkenyl, (un)saturated heterocyclylalkenyl, or (un)saturated bi- or tricyclo condensed

L6 ANSWER 3 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
heterocyclylalkenyl; R3 = H, (un)substituted alkyl, aryl, alkoxycarbonyl; Ar = a divalent group derived from arom. hydrocarbon, (un)satd. 5- to 7-membered heterocyclic group, or (un)satd. bi- or tricyclo condensed heterocyclic group; X = a single bond, a single bond, each (un)substituted
linear or branched C1-3 alkylene, C1-3 alkenylene, or C1-3 alkynylene, CO; G = halo, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, alkoxycarbonyl, N-alkylamino, N,N-dialkylamino, each (un)substituted (un)satd. bi- or tricyclo condensed hydrocarbyl, (un)satd. 5- to 7-membered heterocyclyl, or (un)satd. bi- or tricyclic heterocyclyl] are prepd. Also disclosed is (1) an agent for inhibiting the agglutination and/or deposition of an amyloid protein or amyloid-like protein or (2) a preventive and/or remedy for conformational diseases or diseases caused by amyloid accumulation, which contains the compd. I, its salt, or solvate thereof. In particular, disclosed is a preventive and/or remedy for Alzheimer's disease, Down's syndrome, Creutzfeldt-Jakob disease, type II diabetes, dialysis amyloidosis, AA amyloidosis, Gerstmann-Straussler-Scheinker (GSS) syndrome, Muckle-Wells syndrome, localized atrial amyloidosis, thyroid medullary carcinome, skin amyloidosis, localized tuberous amyloidosis, AL amyloidosis, AA amyloidosis, familial Mediterranean fever, Parkinson's disease, tauopathy, ALS, or CAG repeat disease. A radiodiagnostic agent ownty. radioiodide-labeled, in particular radioactive iodine-labeled compd. I is also disclosed. Thus, 3.0 g 4-isoxol-5-ylphenylhydrazine and 0.61 g 4-pyridinecarboxaldehyde were heated in ethanol at reflux overnight to give, after recrystn. from ethanol, 3.03 g 4-pyridinecarboxaldehyde N-[4-(isoxol-5-yl)phenyl]hydrazone (I2). II inhibited the formation of amyloid from amyloid β protein with IC50 of 2.54 μM vs 0.87 and 3.23 μM for Congo Red and 2-(1,1-dicyanopropen-2-yl)-6-dimethylaminonaphthalene (DDNP), resp.
IT 774236-55-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone derivs. as inhibitors of agglutination and/or deposition of amyloid protein or amyloid-like protein)
RN 774236-55-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

IT 774236-56-5P 774236-57-6P 774236-58-7P
774236-59-8P 774236-60-1P 774236-61-2P
774236-62-3P 774236-70-2P 774236-71-3P
774236-75-8P 774236-80-3P 774236-83-6P
774236-91-8P 774236-92-9P 774237-28-4P
774237-29-5P 774237-34-2P 774237-35-3P
774237-36-4P 774237-37-5P 774237-67-1P
774237-68-2P 774237-69-3P 774237-70-6P
774237-74-0P 774237-77-3P 774237-78-4P
774237-79-5P 774237-80-8P 774237-81-9P
774237-86-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone derivs. as inhibitors of agglutination and/or deposition of amyloid protein or amyloid-like proteins)

RN 774236-56-5 CAPLUS
CN Hydrazinecarboxylic acid, 1-[4-(5-oxazolyl)phenyl]-2-(4-pyridinylmethylene)-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 774236-57-6 CAPLUS
CN Acetic acid, 1-[4-(5-oxazolyl)phenyl]-2-(4-pyridinylmethylene)hydrazide (CA INDEX NAME)

RN 774236-58-7 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-methyl-2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774236-59-8 CAPLUS
CN Hydrazinecarboxylic acid, 1-(4-(4-iodo-5-oxazolyl)phenyl]-2-(4-pyridinylmethylene)-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 774236-60-1 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[4-(4-iodo-5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774236-61-2 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[3-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774236-62-3 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[2-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774236-70-2 CAPLUS
CN Hydrazinecarboxylic acid, 2-[4-[4-(hydroxymethyl)-5-oxazolyl]phenyl]-2-(4-pyridinylmethylene)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 774236-71-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[4-[4-(hydroxymethyl)-5-oxazolyl]phenyl]hydrazone (CA INDEX NAME)



RN 774236-75-8 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[4-[4,5-dihydro-2-oxazolyl]phenyl]hydrazone (CA INDEX NAME)





RN 774236-92-9 CAPLUS
CN 3-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774237-28-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[2-iodo-4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774236-80-5 CAPLUS
CN Methanone, phenyl-4-pyridinyl-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774236-83-8 CAPLUS
CN Ethanone, 1-(4-pyridinyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774236-91-8 CAPLUS
CN 2-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774237-29-5 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[3-iodo-4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774237-54-2 CAPLUS
CN 4-Pyridinecarboxaldehyde, 3-iodo-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-35-3 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-iodo-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-36-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-fluoro-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-68-2 CAPLUS
CN 3-Pyridinecarboxaldehyde, 6-fluoro-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-69-3 CAPLUS
CN 3-Pyridinecarboxaldehyde, 6-(4-methyl-1-piperazinyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774237-37-5 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-(4-methyl-1-piperazinyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-67-1 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-(dimethylamino)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 774237-70-6 CAPLUS
CN 3-Pyridinecarboxaldehyde, 6-(dimethylamino)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-74-6 CAPLUS
CN 4-Pyridinecarboxaldehyde, 1,2,3,6-tetrahydro-1-(phenylmethyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

RN 774237-77-3 CAPLUS
CN 4-Pyridineacetic acid, α-[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-, ethyl ester, (α2)- (CA INDEX NAME)

Double bond geometry as shown.



RN 774237-80-8 CAPLUS
CN 4-Pyridineacetamide, N-(2-hydroxyethyl)-α-[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-, (α2)- (CA INDEX NAME)

Double bond geometry as shown.



RN 774237-81-9 CAPLUS
CN 4-Pyridinecarbohydrazonoyl chloride, N-[4-(5-oxazolyl)phenyl]- (CA INDEX NAME)



RN 774237-78-4 CAPLUS
CN 4-Pyridineacetic acid, α-[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-, hydrochloride (1:1), (α2)- (CA INDEX NAME)

Double bond geometry as shown.



RN 774237-79-5 CAPLUS
CN 4-Pyridineacetamide, α-[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]- (CA INDEX NAME)

RN 774237-86-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, 2-[3-fluoro-4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              11.38     199.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                              -1.60      -1.60

STN INTERNATIONAL LOGOFF AT 11:15:43 ON 22 OCT 2008
```